POPULARITY
94 episodes with bcma
38 episodes with bcma
23 episodes with bcma
17 episodes with bcma
22 episodes with bcma
22 episodes with bcma
22 episodes with bcma
22 episodes with bcma
22 episodes with bcma
14 episodes with bcma
9 episodes with bcma
131 episodes with bcma
7 episodes with bcma
7 episodes with bcma
7 episodes with bcma
3 episodes with bcma
7 episodes with bcma
7 episodes with bcma
In this episode I rundown the main card of UFC 330 and give my thoughts . Plus, I guess it's time to visit the King Green situation and tell a little truth. Let me know who ya got in the comments. To be entered into the SUBSCRIBER GIVEAWAY- Subscribe, like, comment.Enjoy. Kru LuckGym - www.LuckysMT.com
In this episode I talk about the MVP PFL merger and how I had a bead on something like this possibly happening. They have at least two big problems that might cause a bump in the road one of them is also the reason they'll succeed. I touch a little on UFC Belgrade and Navajo Stirling being dubbed the white Israel Adesanya. Enjoy,Kru LuckGym - www.LuckysMT.com
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression. Key topics included: The current treatment algorithms for late relapse refractory multiple myeloma The significance of antigen expression in guiding treatment decisions The role of bispecific antibodies like teclistamab and talquetamab Managing side effects and improving patient quality of life The importance of collaboration between community hematologists and tertiary care centers Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://x.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Subscribe for more insights and updates on oncology treatments! #MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics: Introduction (00:00) Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44) Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00) Utility of Belantamab Mafodotin in R/R MM (49:29) Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01) CME information and select publications
Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice. Presenters:Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia Mohamad Mohty, MD, PhD Sorbonne University Paris, France Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode I tell you why I am going against the grain and choosing Ian Machado Garry to beat Islam Makhachev at UFC 330. Or am I?Enjoy, Kru LuckGym - www.LuckysMT.comLike, Comment, Subscribe for the UFC card giveaway.
In this podcast, 2 leading haematologists discuss the unmet needs in multiple myeloma in the second-line setting and beyond, considerations for treatment decisions, and the evolving treatment landscape with a focus on B-cell maturation antigen-targeted bispecific antibodies, a rapidly advancing class of treatments in this setting. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03715-z. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including: Contemporary Risk Stratification Interpreting Evidence for Early Intervention Treatment vs Observation: Patient Selection Treatment Selection and Sequencing Considerations Safety, Monitoring, and Supportive Care Implementation in Practice Shared Decision-making and Patient Communication Emerging Therapies and Clinical Trials Presenters: Natalie S. Callander, MD Professor of Medicine Director, Myeloma Clinical and Cellular Therapy Program University of Wisconsin Carbone Cancer Center Madison, Wisconsin Tom Martin, MD Professor of Medicine Associate Chief, Hematology/Oncology UCSF Medical Center San Francisco, California Link to full program:https://bit.ly/4wqpYzU Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting scientific breakthroughs and regulatory developments that are shaping the future of healthcare. Eli Lilly's retatrutide, a promising small molecule GLP-1 receptor agonist, has achieved significant results in Phase 3 trials, leading to an impressive 22.6% weight loss in patients with obesity and cardiovascular disease. This breakthrough underscores the potential of GLP-1 receptor agonists in transforming treatment paradigms for metabolic disorders. The drug's ability to target metabolic pathways associated with obesity and type 2 diabetes could herald a new era in managing these conditions, offering hope for millions struggling with obesity—a major risk factor for cardiovascular diseases. In oncology, Johnson & Johnson has unveiled remarkable results with its combination therapy of Tecvayli (teclistamab) and Talvey (talquetamab), achieving an 89% reduction in disease progression risk for multiple myeloma patients during a Phase 3 trial. This bispecific antibody approach targets BCMA and GPRC5D, representing a significant advancement in treating this challenging hematological malignancy. Such efficacy could set a new standard for multiple myeloma treatment strategies, enhancing patient outcomes considerably. Meanwhile, GSK has made strides with FDA approval of Jideytro (zidesamtinib) for ROS1-positive metastatic non-small cell lung cancer. This small molecule kinase inhibitor targets the ROS1 mutation, providing a targeted therapeutic option that aligns with the progress in precision medicine—offering treatments based on patients' genetic profiles. On the regulatory front, the passage of FDA Modernization Act 3.0 by the House reflects a shift towards more ethical preclinical testing methods by updating outdated animal testing regulations. This legislative change could expedite drug development timelines and improve the translation of preclinical findings into clinical success—an encouraging step forward for the industry. In China, Takeda's Orzeyful (oveporexton) received approval as the first ox2r agonist for narcolepsy type 1 treatment. This approval marks advancements in addressing neurological conditions through novel mechanisms targeting orexin receptor pathways. Similarly, Haisco Pharmaceutical's Ciprocopan has been approved as an oral complement factor B inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), offering a more convenient treatment option compared to existing therapies. AstraZeneca's Etcamah (camizestrant) gained EU approval following its success in Phase 3 trials for estrogen receptor-positive, HER2-negative advanced breast cancer. As an oral selective estrogen receptor degrader (SERD), it presents an innovative approach to targeting ESR1 mutations and could be combined with CDK4/6 inhibitors to enhance therapeutic efficacy further. On the strategic collaboration front, partnerships like those formed by Arcus Biosciences with Aveo Oncology and Summit Therapeutics exemplify efforts to advance drug discovery capabilities, particularly in kidney cancer treatments. These collaborative approaches reflect a broader trend in oncology therapeutics development. Financial investments are also fueling growth within the sector. Mentari Therapeutics secured $200 million to propel its migraine prevention biologics pipeline forward, highlighting confidence in biologic treatments for neurological disorders. Beone Medicines has committed $300 million to expand manufacturing capabilities, demonstrating ongoing investment in infrastructure to support future drug production demands. In summary, these developments illustrate significant scientific advancements and regulatory progress within the pharmaceutical and biotech industries. The implications are profound: improved patient care through innovative therapies, enhanced precision medicine approaches tailored to genetic mutations, and accelerated drug discovery processes facilitated by evolving regulatory frameworks. As these trends continue to evolve, they promise to reshape patient outcomes and redefine standards across various therapeutic areas. Thank you for tuning into Pharma Daily today. Stay informed as we continue to bring you updates on cutting-edge advances that are transforming healthcare worldwide.Support the show
In this episode I talk about UFC Oklahoma, Usman and Adesanya slander, and some random news. I also, talk about a recent Brandon Royval interview in which he expressed some frustrations with being told he doesn't have enough followers. This asks the question "what is the role of the promoter?" Hope you enjoy.Don't forget to Subscribe and comment to get entered into the UFC card giveaway. Peace, Kru LuckGym - www.LuckysMT.com
In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including: The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How to set up and maintain a REMS program Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Syeda Saba Kareem, PharmD, BCOP Clinical Pharmacy Supervisor Malignant Hematology Moffitt Cancer Center Tampa, Florida Sara A. Scott, PharmD, BCOP Clinical Pharmacy Specialist, Multiple Myeloma Emory Winship Cancer Institute Atlanta, Georgia Link to full program: https://bit.ly/3RUyrMx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this video I talk about Aura and what happens when they lose their aura and what we learned as fans from this Conor McGregor debacle. Plus I give you a real example of what aura is at the end of the video. EnjoyGiveaway: UFC card packs will be given out to some lucky subscribers at 600, 700, etc. To enter, Like, Comment, Subscribe on one these videos leading up to the goal.Peace and blessings LuckGym- www.LuckysMT.com
This is the main card rundown and discussion for ufc Oklahoma with the main event being Kamaru Usman one of the greatest welterweights of all time against the South African former middleweight champion Dricus Du Plessis. Who ya got?Enjoy. Kru LuckGym - www.LuckysMT.com
Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include: Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effects Presenters: Jesus Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Amrita Krishnan, MD, FCAP Nason Hollingworth Family Chair in Myeloma Director, Judy and Bernard Briskin Center for Myeloma Professor Hematology/HCT Executive Director of Hematology City of Hope Orange County Irvine, California Content based on an online CME program supported by an educational grant from Johnson & Johnson. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join our host Lorenda and Illana Hester, Executive Director of The Old School House Arts Centre, arts advisor, and coordinator of Creative Coast, for a conversation about leadership, accountability, bravery, and community-building. Explore leadership as a collaborative practice grounded in care, curiosity, transparency, vulnerability, and a willingness to learn from failure, and reflect on how arts and cultural organizations can build trust, share decision-making, challenge hierarchical systems, and create space for meaningful connection. Resources: BCMA - 2SLGBTQIA+ Cultural Professionals Network QP — The Old School House Arts Centre The Old School House Arts Centre
In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including: A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice Identifying and Managing Adverse Events Associated With BCMA-Directed Agents Presenters: Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP Clinical Oncology Pharmacy Manager Atrium Health Levine Cancer Institute Charlotte, North Carolina Anthony Perissinotti, PharmD, BCOP Hematology Clinical Pharmacist Specialist University of Michigan Ann Arbor, Michigan Link to full program:https://bit.ly/4gCsgXt Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Join our host Lorenda and Q̓íx̌itasu Elroy White, Haíɫzaqv archaeologist, hereditary chief, elected council member, historian, singer, and dancer, for a conversation about leadership, cultural stewardship, archaeology, and repatriation. Explore the M̓ṇúxvit approach, grounded in Haíɫzaqv laws, knowledge, relationships, and collective responsibility, and reflect on what changes when museum objects are understood as belongings connected to living families, ceremonies, songs, and inherited rights. Resources: Haíɫzaqv archeologist practices M̓ṇúxvit approach to ancestral work | Coastal First Nations M̓ṇúxvʔit model for centering Indigenous knowledge and governance - PMC After 113 years, Royal B.C. Museum hands back chief's seat to coastal First Nation
Join our host Lorenda and Wedlidi Speck, hereditary chief and Vice President for People, Culture and Reconciliation at the Royal BC Museum, for a conversation about leadership, healing, accountability, and decolonization. Drawing on his work as a therapist, cultural leader, and museum professional, Wedlidi reflects on the importance of listening, humility, psychological and cultural safety, and collaborative decision-making. Explore how values become meaningful through action, how circles can reshape hierarchical leadership, and how Indigenous and non-Indigenous museum professionals can examine the ongoing impacts of colonization while building relationships grounded in respect, responsibility, courage, and care. Resources: Gigame'dzikas (Many Chiefs Project)
Join our host Lorenda and Michelle Richard and Emma Wilton from the Sooke Region Museum for a conversation about community engagement, leadership, and reimagining a local museum. Ahead of the museum's 50th anniversary, Michelle and Emma share how community feedback is guiding a complete refresh of its permanent exhibits. Explore the challenges of widening historical narratives, recognizing bias, improving accessibility, and creating space for more people to see themselves reflected in the museum while discussing transparency, accountability, risk-taking, and the importance of listening, learning, and adapting while caring for the stories and belongings entrusted to their organization. Resources: Sooke Region Museum Interior Exhibit Refresh - Sooke Region Museum Sooke Night Market
Join our host Lorenda and Sally Kim, Objects Conservator at the Royal BC Museum, for a conversation about accessibility, conservation, relationship-building, and repatriation. Sally reflects on her experiences as a deaf museum professional and explores how museums can move beyond accommodation toward meaningful accessibility grounded in listening, transparency, universal design, and disability justice. Consider how collaboration, cultural knowledge, and human connection can reshape conservation practice and create more welcoming, equitable, and responsive museums. Resources: Signs by d-Deaf Conservators Accessibility - BCMA M̓ṇúxvʔit model for centering Indigenous knowledge and governance - PMC After 113 years, Royal B.C. Museum hands back chief's seat to coastal First Nation
In this episode I give you 5 reasons that Conor Mcgregor can beat Max Holloway as well as 5 reasons Max beats Conor at UFC 329. Also, a little commentary at the end. Don't forget to subscribe to be a part of the giveaway. UFC cards galore. Peace,Kru Luck
In this episode I talk about the sometimes perilous journey post career. What happens after years of damage and the emotional stress of trying to maintain a career? Fighters often lose there feelings of self-worth and suffer from a long list of health issues. Let's talk about it. Also, I give an update on an increase in the UFC card giveaway!!Hope you enjoy>Peace ad blessings,Kru LuckGym - www.LuckysMT.comInsta - @Luckysmuaythai
In this episode I talk about fouls in MMA. Is it the gloves, the refs, is it intentionally done? Let's discuss. Also, I'm doing an UFC card giveaway to try to raise subscriptions. To enter just Like, Comment, Subscribe on any video leading up to the goal. Then go to Instagram and Follow the gym @Luckysmuaythai When we get to 750 subscribers on this channel the cards could be yours. Good Luck! Enjoy the videoKru LuckGym - www.LuckysMT.com Insta- @Luckysmuaythai
In this episode I run through the Freedom 250 fight card and controversy surrounding Cyril Gand and Alex Pereira, Josh Hokit spewing $h!t about Michelle Obama, and Ilia getting absolutely destroyed by Justin Gaethje. Let's go!Gym - www.LuckysMT.com
Host: Steve Jackson, PharmD Guest: Nisha Joseph, MD This is a non-certified educational series produced and controlled by ReachMD. As BCMA-directed therapies move into earlier lines of care, more patients with relapsed and refractory (R/R) multiple myeloma are entering a treatment space with limited consensus on optimal sequencing strategies. In this conversation with Dr. Steve Jackson, Dr. Nisha Joseph explores how disease biology, immune exhaustion, prior treatment response, and patient-specific factors can guide therapy selection in this population. She's an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta.
In this episode I discuss all of the wild things that hit the MMA headlines over the last couple of weeks. I also give my indecisive picks for the fights. Welcome to the spectacle. Happy Birthday America!
In this episode I talk about how the Freedom 250 card is shaping up. So far there's heat, bugs, bands dropping out and is it a USA birthday or a Trump birthday. Also, Dana says non of this is political including him. So let's talk about it.Enjoy the listen.LuckyGym - www.LuckysMT.com
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of fascinating advancements in the industry, each with significant implications for future patient care and drug development. At the recent American Society of Clinical Oncology (ASCO) 2026 conference, Akeso's ivonescimab, a pioneering PD-1xVEGF bispecific antibody, demonstrated a 34% reduction in death risk when combined with chemotherapy for first-line lung cancer treatment. This marks a pivotal moment in cancer therapeutics, illustrating how bispecific antibodies can enhance treatment efficacy. The evolving landscape of cancer treatment continues to highlight the importance of these innovative approaches. Johnson & Johnson's Erleada has shown promising results in prostate cancer, achieving positive outcomes in its Phase 3 Proteus study. The trial emphasized the efficacy of Erleada when administered perioperatively to prostate cancer patients, indicating a shift towards more personalized and comprehensive care that incorporates targeted therapies before and after surgery. In another significant breakthrough, Lilly's Retemvo exhibited dramatic results in early-stage lung cancer with RET fusion-positive markers, reducing disease progression or death by 83% as adjuvant therapy. This underscores the critical role of molecularly targeted therapies for patients with specific genetic profiles, offering hope for improved survival outcomes. On the frontlines of infectious diseases, Shionogi's COVID-19 antiviral Xocova has received FDA approval as a post-exposure prophylactic. This milestone highlights the challenging yet dynamic landscape of antiviral drug development, offering a new tool in managing COVID-19 exposures after previous challenges in demonstrating effectiveness as a treatment. MannKind's inhaled insulin, Afrezza, has been approved for pediatric use. This approval could rejuvenate its market presence by providing a more convenient insulin delivery system aimed at improving adherence and glycemic control among younger patients. In oncology news, Pfizer's Talzenna combination therapy received broader FDA approval for castration-sensitive prostate cancer. This positions it as a competitive option against Johnson & Johnson's PARP inhibitor combination therapy. Additionally, AstraZeneca's Imfinzi and Imjudo combination showed promise in early-stage liver cancer by reducing disease progression risks by 30%, broadening immunotherapy applications. The market dynamics are also shifting with significant strategic movements like Eli Lilly's acquisition of Kelonia Therapeutics for $3.2 billion. This decision is driven by promising in vivo CAR-T data demonstrating unprecedented response rates and reflects the increasing importance of innovative CAR-T therapies in oncology. Eli Lilly's Kelonia Therapeutics' cell therapy showcased an impressive 100% response rate in a Phase 1 trial for relapsed or refractory multiple myeloma. This CAR-T therapy targets the BCMA antigen and could revolutionize treatment paradigms by offering more effective responses. Meanwhile, Pfizer's transformative research on RAS inhibitors holds potential to redefine treatment paradigms in pancreatic cancer—a notoriously difficult-to-treat type due to its complex biology. Revolution Medicines aims to maintain its leadership within this space amidst growing competition. Revolution Medicines also reported compelling results with their KRAS inhibitor, which nearly doubles survival rates for metastatic pancreatic cancer patients harboring KRAS mutations. Given the historically poor prognosis associated with pancreatic cancer, these findings represent a significant advancement in managing this aggressive type. In ovarian cancer research, Gilead's TUB-040 demonstrated a 61% tumor response rate for platinum-resistant ovarian cancer in a Phase 1 trial. This highlights the potential of antibody-drug conjugates (ADCs) to overcome resistance mechanisms and improve outcomes in difficult-to-treat cancers. Regulatory updates include Johnson & Johnson receiving FDA label expansion for Tremfya to inhibit structural joint damage in active psoriatic arthritis patients. This expansion provides broader treatment options for patients suffering from debilitating conditions by reinforcing the role of IL-23 inhibitors in autoimmune disease management. Strategic partnerships are also shaping drug development's future landscape. Notably, Servier's acquisition of Edgewise Therapeutics' muscular dystrophy unit underscores growing focus on rare diseases and neuromuscular disorders. Eli Lilly's agreements with Haisco Pharmaceutical and Hanmi Pharm reflect ongoing R&D investments aimed at expanding therapeutic portfolios across various indications. These developments illustrate a broader trend toward personalized medicine and targeted therapies that enhance treatment efficacy by leveraging specific genetic or molecular characteristics. Despite advancements, challenges remain as exemplified by Oculis' OCS-01 failing Phase 3 trials for diabetic macular edema—highlighting inherent risks in drug development. Overall, these updates underscore significant scientific progress and promise improvements in patient outcomes through novel therapeutic approaches and collaborative efforts within this vibrant industry landscape.Support the show
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/FJB865. NCPD/ILNA credit will be available until May 25, 2027.“Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/FJB865. NCPD/ILNA credit will be available until May 25, 2027.“Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/FJB865. NCPD/ILNA credit will be available until May 25, 2027.“Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/FJB865. NCPD/ILNA credit will be available until May 25, 2027.“Off-the-Shelf” Choices in RRMM: Oncology Nurse Guidance on Delivering Quality Care With BCMA and Non-BCMA Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
In this episode I touch base on the insanity caused by the Sean Strickland vs Khamzat Chimaev fight. MMA on Netflix was fun and we should discuss. Lastly, Conor is back to get pieced up bu Max Holloway!Enjoy. PEACE AND BLESSINGSGym - www.LuckysMT.com
Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics included: Overview of bispecific antibodies, focusing on GPRC5D and BCMA-targeted therapies. Detailed discussion on talquetamab, teclistamab, elranatamab, and linvoseltamab, including dosing, side effects, and management strategies. Insights on managing cytokine release syndrome (CRS), neurotoxicity, and other side effects like dysgeusia, skin toxicity, and infections. Prophylactic measures, including the use of IVIG and tocilizumab, to enhance patient care and quality of life. Whether you're a healthcare professional or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers
In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including: Practical differences among approved bispecific antibodies Toxicity profiles of approved bispecific antibodies When to refer patients for evaluation for immunotherapies Considerations for sequencing bispecific antibodies in the relapsed/refractory setting New findings with combination regimens with bispecific antibodies Program faculty: Doris K. Hansen, MD Assistant Member, Blood and Marrow Transplant and Cellular Immunotherapy H. Lee Moffitt Cancer Center & Research Institute Assistant Professor University of South Florida Morsani College of Medicine Tampa, Florida Link to program page:https://bit.ly/4nufxr2 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode I rundown the main card of UFC 328 and give my picks for the fights. Enjoy.Gym - www.LuckysMT.com
In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies. Presenters: Muhamed Baljevic, MD, FACP Associate Professor of Medicine Division of Hematology-Oncology Department of Medicine Director, Multiple Myeloma Program Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP) Co-Chair, Scientific Review Committee, VICC Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center Nashville, Tennessee Jonathan Ticku, MD Medical Oncologist and Hematologist GU Oncology Lead, Mayo Clinic Health System Assistant Professor of Oncology, Mayo Clinic La Crosse, Wisconsin Link to full program: https://bit.ly/4u0xH6q Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
I give a very vague opininated viewpoint of the main card of UFC Perth. It was a great event with exciting finishes. Carlos Prates vaulted himself closer to the title as JDM moves further away. I also rant about using street fights to sell fights. Hope you enjoy.Peace and BlessingsGym www.LuckysMT.com
In this episode I briefly talk about ONE Championship, I discuss the differences between Pay and Opportunity, I rundown the main card of UFC Perth and is Izzy the guy in the pub?Like and commentGym - www.LuckysMT.com
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.
In this episode I rant about building a fight vs threatening to m^^der someone. Are we Arman fans and how much is he walking that line? Rodtang free, Saenchai showing that IQ is everything.Enjoy, Peace and blessings.Kru/Sensei Luck
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore some of the pivotal shifts and breakthroughs shaping the industry and their implications for drug development and patient care. In oncology, Merck & Co.'s Welireg triplet therapy faced a setback in its Phase 3 trial for first-line treatment of kidney cancer. Despite previous successes, this outcome underscores the complexity of developing oncology treatments and illustrates the ongoing need for innovative approaches to meet diverse patient needs. Meanwhile, Roche has reported promising results for Enspryng in its Phase 3 trial, demonstrating a 68% reduction in relapse risk for a rare neuroinflammatory disorder. This success highlights Roche's commitment to addressing unmet needs in rare diseases and paves the way for potential FDA approval. AstraZeneca continues to advance with Ultomiris, which showed significant results in reducing protein levels in urine for IgA nephropathy patients. This success not only expands Ultomiris' indications but also underscores AstraZeneca's focus on rare diseases, positioning them as leaders in this specialized market. Additionally, AstraZeneca's Tozorakimab met primary endpoints in COPD trials, showcasing new possibilities for managing this prevalent respiratory disease. On another front, Zai Lab's strategic evolution from licensing major pharma drugs to developing its own pipeline marks a significant maturation of China's biotech capabilities. This reflects a broader trend of Chinese firms seeking global footprints while navigating regulatory challenges to gain international credibility. Regulatory and strategic news also has its highlights: Pfizer is undergoing changes as its Chief Strategy and Innovation Officer steps down, possibly signaling a shift in strategic direction. Replimune's drastic workforce reduction following an FDA rejection exemplifies the harsh realities biotech companies face in regulatory pathways. Meanwhile, Gilead's retraction from a collaboration with Arcus Biosciences after a Phase 3 failure underscores the risks associated with antibody-based therapies. In other collaborations, Roche's Foundation Medicine is deepening ties with Bristol Myers Squibb to develop new diagnostic targets, illustrating how partnerships can drive innovation by leveraging combined expertise. In industry trends, there's a growing integration of medical affairs with commercial operations to optimize scientific exchange and product launches—this alignment is critical for ensuring new therapies reach patients efficiently. Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion signals an increased focus on in vivo CAR-T capabilities. This acquisition could streamline cancer treatments by engineering T-cells directly within patients' bodies, offering potentially more effective therapeutic approaches. Globally, Biogen has expanded its partnership with TJ Biopharma for Felzartamab rights in China, reflecting strategic moves to penetrate Asian markets. GSK's Blenrep received Chinese approval for treating multiple myeloma, marking a significant advancement with this antibody-drug conjugate targeting BCMA. In Canada, ClearPoint Neuro gained approval for its neuro navigation system, highlighting precision medicine's role in enhancing therapeutic outcomes. The technological landscape is also evolving with Serif pioneering DNA-based therapeutics. Supported by Flagship Pioneering's $50 million investment, these innovations could revolutionize personalized medicine by offering tailored solutions. Ray Therapeutics' $125 million funding advancement in gene therapy candidates targeting retinal degeneration further underscores interest in genetic therapies as viable treatment options. In regulatory landscapes, there's a push for designing neurodegenerative trials that Support the show
Dr. Robert Rifkin, medical oncologist and hematologist at the University of Colorado in Steamboat Springs. He was also a clinical investigator in the trial that led to the approval of BLENREP, a multiple myeloma drug from GSK. Multiple myeloma is the second most common blood cancer, and while the prognosis has dramatically improved, BLENREP is a novel treatment for patients whose disease has relapsed after other therapies. It is the first drug antibody conjugate approved for relapsed multiple myeloma, targeting the BCMA antigen, which is present on nearly all myeloma cells. Robert explains, "This is a condition that is really what I would call a disease of the Medicare population. So the median age of diagnosis is often early 60s, but occasionally you do see the younger patients with more aggressive disease. It's thought that African Americans who contract myeloma also may have a more virulent form of the disease." "Right now we live in a great day and age where we have a tremendous number of good treatments, both upfront, which we really won't be discussing today. And then in patients that have unfortunately relapsed and failed other lines of therapy, that's where the exciting new drug BLENREP comes into play. It's going to have a very specific slot in the myeloma armamentarium." "So BLENREP is unique in that it targets something on the myeloma cells called the BCMA target or B-cell maturation antigen target. That's expressed in 98% of patients with myeloma. So it provides a really great target to shoot at, if you will. Right now, we really have sort of three main classes of therapy to go after it: CAR T-cells and bispecific antibodies that your audience will likely be familiar with. This one is unique in that it's the first drug antibody conjugate approved to treat myeloma. So it's not a cellular therapy, but instead it's a molecule that has the BCMA that binds to the myeloma cells, and then it unloads a payload to kill the myeloma cells. So that's nice. You don't have to go to a huge center with experience in cellular therapies. It can be done readily in the community." #MultipleMyeloma #Oncology #BLENREP #BloodCancer #Belamaf #CancerResearch #Hematology #ClinicalTrials #PrecisionMedicine #CancerTreatment #MedicalAdvancement blenrephcp.com Download the transcript here
Dr. Robert Rifkin, medical oncologist and hematologist at the University of Colorado in Steamboat Springs. He was also a clinical investigator in the trial that led to the approval of BLENREP, a multiple myeloma drug from GSK. Multiple myeloma is the second most common blood cancer, and while the prognosis has dramatically improved, BLENREP is a novel treatment for patients whose disease has relapsed after other therapies. It is the first drug antibody conjugate approved for relapsed multiple myeloma, targeting the BCMA antigen, which is present on nearly all myeloma cells. Robert explains, "This is a condition that is really what I would call a disease of the Medicare population. So the median age of diagnosis is often early 60s, but occasionally you do see the younger patients with more aggressive disease. It's thought that African Americans who contract myeloma also may have a more virulent form of the disease." "Right now we live in a great day and age where we have a tremendous number of good treatments, both upfront, which we really won't be discussing today. And then in patients that have unfortunately relapsed and failed other lines of therapy, that's where the exciting new drug BLENREP comes into play. It's going to have a very specific slot in the myeloma armamentarium." "So BLENREP is unique in that it targets something on the myeloma cells called the BCMA target or B-cell maturation antigen target. That's expressed in 98% of patients with myeloma. So it provides a really great target to shoot at, if you will. Right now, we really have sort of three main classes of therapy to go after it: CAR T-cells and bispecific antibodies that your audience will likely be familiar with. This one is unique in that it's the first drug antibody conjugate approved to treat myeloma. So it's not a cellular therapy, but instead it's a molecule that has the BCMA that binds to the myeloma cells, and then it unloads a payload to kill the myeloma cells. So that's nice. You don't have to go to a huge center with experience in cellular therapies. It can be done readily in the community." #MultipleMyeloma #Oncology #BLENREP #BloodCancer #Belamaf #CancerResearch #Hematology #ClinicalTrials #PrecisionMedicine #CancerTreatment #MedicalAdvancement blenrephcp.com Listen to the podcast here
Dr. Monty Pal speaks with internationally acclaimed hematologists Dr. Vincent Rajkumar and Dr. Saad Usmani about the AQUILA trial in high-risk smoldering multiple myeloma, as well as advances in CAR-T and other evolving treatment strategies in the myeloma space. TRANSCRIPT Dr. Monty Pal: Hello everyone and welcome to the ASCO Daily News Podcast. I'm your host, Monty Pal. I'm a medical oncologist, underline medical oncologist, a professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. You're going to understand why I underlined "medical oncologist" there. I'm actually on the line today with two amazing hematologists. Today, we're going to actually explore treatments for high-risk smoldering multiple myeloma following the FDA's approval last year of daratumumab for the first-ever treatment of this indication. Now, this is based on the AQUILA trial, and this represents a huge shift in our traditional watch-and-wait approach to active disease interception. We're going to consider whether this landmark trial published in The New England Journal translates to day-to-day practice. I think it does, and we'll certainly make an argument for that. And I'm so fortunate today to have two internationally acclaimed experts here in the conversation: Dr. Vincent Rajkumar, senior author on the manuscript, and Dr. Saad Usmani, also an expert in his own right in myeloma. Dr. Rajkumar is the lead investigator of the AQUILA study. He's a professor of medicine and consultant in the divisions of hematology and hematopathology at the Mayo Clinic in Rochester, Minnesota. He actually chairs the Myeloma, Amyloidosis, Dysproteinemia Program. He is also editor-in-chief of the Blood Cancer Journal. Dr. Usmani, he and I actually go way, way back. We actually did the AACR Molecular Biology in Clinical Oncology course, I want to say in 2006, so this is our 20-year anniversary, Saad. He's the chief of the myeloma service at the MSK Cancer Center and a professor of medicine at the Weill Cornell Medical College in New York. Saad, Vincent, welcome. Dr. Saad Usmani: Thank you so much for having me, Monty. Dr. Vincent Rajkumar: Yeah, thanks, Monty. A pleasure to be here. Dr. Monty Pal: Thanks. And just a quick note for our listeners, all of our disclosures are available in the transcript of this episode. First off, Saad, did I get that right? Was it 2006 when we did that course together? Dr. Saad Usmani: Yeah, 20 years. We are coming up to our 20-year anniversary. It's remarkable to have seen our careers move the way they have, Monty. Dr. Monty Pal: Oh my gosh. And for all the fellows who are on the line, that AACR Molecular Biology and Clinical Oncology course, it's sometimes overlooked. Wonderful primer on translational science. Okay, now we're going to get to the heart of the matter here, the AQUILA trial. So this was a study, Vincent, that you led. I wonder if you'd walk us through the primary endpoints in the study. What are we looking at in the AQUILA trial specifically? Dr. Vincent Rajkumar: Thanks so much. Again, as you mentioned, smoldering multiple myeloma has just been a condition that we watch and wait. And the first thing that I want to clarify here is that the AQUILA trial is looking at only a subset of smoldering multiple myeloma. That is the high-risk smoldering multiple myeloma. It was defined the way high-risk smoldering myeloma was defined at the time the trial was designed. It randomized 390 patients. One arm got daratumumab single agent in an attempt to delay progression to active myeloma and possibly prolong survival. And the other arm was the traditional observation. The primary endpoint, therefore, was time to active multiple myeloma. Other endpoints included time to when patients needed to start therapy for active multiple myeloma, which can vary based on physician judgment, and overall survival. Of course, response rate, complete response rate, and others were also endpoints. Dr. Monty Pal: That's interesting. And you know, I wanted you to riff a little bit on this definition of high-risk smoldering myeloma. Can you tell our audience how that's sort of evolved over the years? Dr. Vincent Rajkumar: Yes. I mean, if you step back, monoclonal gammopathy of undetermined significance has only a 1% per year risk of progression. Smoldering multiple myeloma, all comers have a 10% per year risk of progression. And over the years, trials have been done in the whole population, and then more recently, we felt we should really focus on the people with high-risk smoldering, defined as a 50-50 risk of progression in 2 years. That's like a 25% per year risk of progression in the first 2 years, which is a very high risk for the patient and something that would justify prophylactic intervention. And that definition initially was based on just high levels of monoclonal protein like more than 3 grams, the IgA subtype of myeloma, the suppression of uninvolved immunoglobulins. Others have used bone marrow flow cytometry markers, cytogenetics. Those combinations of factors were available at the time the AQUILA trial was designed, and a select combination was used. Later on, we found that we could match almost all of that in a very simple risk stratification using just the percentage of bone marrow plasma cells, the level of the M-spike, and the free light chain ratio, all three of which are available to all patients with smoldering at the time of diagnosis. So you don't need any special testing. So more than 20% plasma cells, more than 20 for the light chain ratio, and more than 2 grams for the M-spike. If someone has any two of the three, that is high-risk smoldering multiple myeloma according to the IMWG, but that definition, of course, came in 2020 after the AQUILA trial completed accrual. Dr. Monty Pal: That's interesting because this sort of flips the traditional paradigm where biomarkers get more and more complex as time goes on. Am I right in saying this sort of simplifies things a little bit? It uses standard laboratory or clinical parameters to gauge this category? Dr. Vincent Rajkumar: Absolutely. People were using suppression of uninvolved immunoglobulins, and those levels are not standardized, often vary by race. Also, the other aspect was the abnormal plasma cells on flow cytometry. Again, labs define it differently. So this makes it much more simple. But the IMWG also did a separate exploratory cohort within that paper where we added cytogenetics and we added scoring systems to improve on this further. So it simplified it for regular clinical practice and for like trials. But if you have a patient in front of you, the IMWG paper also has more complex scoring systems where you can take more than 20; 21 is more than 20, so is 51. And so, you can use the actual numbers that a patient has, additional variables like cytogenetics, and get a more refined estimate of what is the true risk of progression. Dr. Monty Pal: That's really helpful. Now, you told us about the primary endpoints, you've helped us define high-risk smoldering myeloma. Can you give us a sense of the top-line results from AQUILA? Dr. Vincent Rajkumar: Yes, I think the most important one was the primary endpoint, time to multiple myeloma, was at 5 years, the progression-free survival was 63% in the daratumumab arm compared to 41% in the observation arm. So, you know, approximately 60% of patients in the observation arm had already progressed by 5 years. And that number was about 40% for the daratumumab arm. We also looked at time to starting myeloma therapy, which is clinically actually quite meaningful because, you know, myeloma therapy means patients get a quadruplet for induction, they get stem cell transplant, they get endless maintenance, they get ongoing therapy virtually for the entire duration. So, preventing the need for myeloma therapy is in and of itself, I think, a major endpoint. And that at 3 years, 40% of people in the observation arm required full myeloma therapy compared to only 20% in the daratumumab arm. So there's a significant reduction in the risk of developing active myeloma as well as the need for myeloma therapy by using a time-limited 3 years of daratumumab single agent. Dr. Monty Pal: Perfect summary of the results. And maybe, Saad, I'm going to bring you into the conversation now. How does this sort of influence your day-to-day practice for smoldering myeloma? Is this something that you've incorporated for that high-risk subset? Dr. Saad Usmani: Thank you, Monty, and I agree. I think that's a really nice summary from Vincent. This study is very important for several reasons. It's actually the third clinical trial that has demonstrated that patients who are in the high-risk smoldering myeloma category benefit from an early intervention that delays the progression to active myeloma or to end-organ damage. And so having a nuanced discussion with our patients in the clinic becomes very important. Having this discussion around as an option becomes very important. And like Vincent said, when we look at that high-risk smoldering myeloma patient population, someone who has 22, 23% plasma cells versus, you know, 45, 50, you know, it's going to be a different discussion each time. But I think it's a very important first step. And I think this sets up the stage for us to design clinical trials where we can ask other questions on what would be better than daratumumab alone in terms of delaying progression in these patients. The other thing that I do want to highlight, and Vincent touched upon this a little bit, that the treatment in this clinical trial was for a fixed duration of treatment. So it was not forever treatment. This is maybe something that Vincent, you can even comment on a little bit more because the question we get after having this discussion is, "Okay, what do we do with patients who are going to be progressing to active myeloma?" Whether we can utilize anti-CD38 therapies for those. So Vincent, I would love your take on this too. Dr. Vincent Rajkumar: Yeah, I think, you know, the main philosophical change for me was previously, the thing was 'don't treat', and now for high-risk smoldering multiple myeloma, the question is, is daratumumab the best treatment or can we do something better? And those trials are thankfully ongoing. One of them has already completed accrual, isatuximab-len-dex versus len-dex. And another one is ongoing in ECOG, almost close to finishing accrual. And in the future, we'll be trying to see if we can use early intervention to even cure and prevent progression altogether. So we are in this phase where we have one approved regimen, one approved drug, and we are not sure whether we can improve on that. The question is, "is a myeloma-like therapy better than monotherapy" would be the next question, and then what would we do further beyond that? In this context, whenever we have patients like this, one of the questions that comes up, as Saad mentioned, is how does this affect newly diagnosed myeloma therapy if somebody has been treated for smoldering and things like that? How will they be considered for clinical trials? Would they be considered as relapse myeloma or still newly diagnosed myeloma? And those are important discussions for clinical trialists to keep in mind, but I think for clinical practice, your duty is to the patient in front of you. If they have high-risk smoldering myeloma and there's data that there's treatments that can delay progression significantly, delay the need for myeloma therapy significantly, that's the highest priority. We'll cross that bridge. There are so few patients going on clinical trials right now that if such a patient were to later on progress and wants to enter in a newly diagnosed myeloma trial later, years later, we can figure that out later. I feel like the most important discussion is what to do for that patient today. I still prefer a clinical trial if one was available. If one was not available, I'd prefer early intervention, but have an informed discussion with the patient because some of them may wish to delay therapy still. Some of them may have very borderline numbers that you want to watch them closely. Some of them may be having other comorbidities that prevent need for therapy. Some of them maybe have had the smoldering for a long time and you already know it's stable. So a lot of factors go in, and I think it's not a one-size-fits-all. Dr. Monty Pal: This is a terrific discussion, and you know, it sort of segues into maybe a question around biology. And this is something I was going to get to a little bit later, but Saad, I'm glad you brought it up. I'll liken it to the only thing I know, which is kidney cancer. So, you know, in kidney cancer, we use checkpoint inhibitors as adjuvant therapy. And there's this question of whether or not it breeds some resistance in the localized setting to ultimately what the patient might potentially be exposed to in the metastatic setting. Tell me your thoughts on this, Vincent, then maybe Saad separately. If you treat a patient with daratumumab in this high-risk smoldering setting, could it theoretically sort of limit options in the refractory setting now that we have regimens like DRBD that are kind of being utilized, or daratumumab with teclistamab? Vincent, I'll throw that to you first. Dr. Vincent Rajkumar: This is a great question, and it's usually asked when we've done the lenalidomide trials actually. We try to put the question back. If that was your concern, how would you actually solve it? Is it really biology that's going to answer that? Or is it a randomized trial? So the experiment has been done three times now where early intervention has been given. And if there was some detriment because of that, that would be reflected in the overall survival. In all three trials, there's no such detriment seen. In the first lenalidomide-dex trial, there was an improvement in overall survival. In the AQUILA trial again, the confidence interval doesn't cross one, and patients had better long-term survival on AQUILA, but certainly not less. We've also examined PFS2 data, and that doesn't seem to be affected. So yes, there is a theoretical concern, and that concern cannot be allayed for new treatments which we have not even tried, like tec-dara, and whether that effect would be there or not. But so far, I don't see it. And I think the onus is on proof of that in order to prevent people from getting early therapy. Dr. Monty Pal: Yeah. Saad, your thoughts on that? And before you jump in, I'll mention, we're kind of taking the same approach in kidney cancer, we're trying to really do studies to see whether or not, you know, immunotherapy rechallenge in these contexts, you know, really lends any substantial benefit. So far, the results have been interesting. I don't think we have enough numbers as yet to capture the impact of adjuvant therapy as it translates to metastatic, but I see so many similarities between the scenarios that you're facing in myeloma and what we're facing in RCC. Saad, your thoughts? Dr. Saad Usmani: Thanks, Monty. I'll go back to something that Vincent alluded to a few minutes ago about the way that we risk-stratify patients within smoldering myeloma. Right now, we are relying more on a disease burden-based stratification looking at the percentage of plasma cells in the bone marrow, the monoclonal protein, as well as the involved light chain versus the uninvolved light chain ratio. However, there are efforts underway to actually incorporate genomics into that schema and try to refine that definition of high-risk smoldering. And there have been two papers that came out in the latter half of last year. In fact. Dr. Rajkumar and I are co-senior authors on one effort where we can identify genomic myeloma in patients in precursor conditions. One of the key things that came out of that effort was that within the high-risk smoldering myeloma category, about 90% of the patients are genomically myeloma. So this whole debate of whether we need to intervene for those patients, I think, you know, we have sufficient biologic evidence that yes, we need to intervene for those patients. I think that the next real step, like Vincent stated, is how do we intervene in those patients? And those clinical trials kind of are ongoing. We will probably need to have more validation of those genomic models being incorporated, but that's what I see in the future. I wouldn't be concerned for the patients being seen today with that query about the disease biology evolving because if I'm seeing a patient today in March of the first quarter of 2026 and offering them monotherapy daratumumab in their high-risk smoldering situation for the next 3 years and then they progress to myeloma after another couple of years, we are talking about what would be the treatment options for them in 2031, 2032. So I think the field is moving so fast, we have a lot of novel therapies coming into that frontline setting rapidly, so our options at that time would be very different. So, you know, I just wanted to kind of set up the stage for saying, you know, our tools are getting better in delineating which patients will need that intervention. And then eventually, I think, you know, we'll have much better options for newly diagnosed myeloma patients at the time when they need it in the future. Dr. Monty Pal: Just absolutely brilliant, absolutely brilliant. I love that summary. I think that you're absolutely right in saying that, you know, you've got to think about what you're going to do for that patient sort of in the moment, what's going to optimize their outcome and agree that the landscape is evolving very rapidly. I'd be remiss, Saad, if I didn't ask you about something that I've been following in terms of your career trajectory. You've developed quite a reputation for your leadership in trials looking at CAR T-cell therapies for myeloma. Can you give us a sense of where that stands in broad terms? Dr. Saad Usmani: Certainly, Monty. I think the CAR Ts have slowly made their way from late relapse to early relapse. And now we have clinical trials that have completed accrual in the frontline setting comparing them to standard-of-care treatment for both older myeloma patients or transplant-ineligible patients, as well as younger transplant-eligible patients where we're actually trying to replace transplants with BCMA-directed CAR T-cell therapies. The nuance there would be we want to equal or better the survival outcomes that we've accomplished without compromising on the safety side of things for patients. Those therapies are moving into earlier lines. And more excitingly, you know, that's just the first wave of CARs. The next wave of CAR technology is coming, and it's going to be in vivo CARs where we may not need lymphodepleting chemotherapy, we may not even need as stringent regulatory nuances that we do for cellular therapies today. So, you know, I think the field is moving rapidly, and it's going to be a very interesting landscape to see over the next 5 to 6 years. Dr. Monty Pal: Yeah, you know, it's so interesting. I know in the solid tumor space, we're trying to replicate the success that you've had with CAR T and bispecifics, and I do see some light at the end of the tunnel. I'm seeing some really promising agents being developed, but clearly, we have so much to learn from our colleagues in hematology. Well, I have to tell you, this has just been a phenomenal conversation. Vincent, congratulations on your leadership of the AQUILA trial. Clearly, a big paradigm shift in the field. Saad, thank you for offering your expert insights and really giving us also a glimpse at the future of myeloma. Really appreciate having you both on the podcast today. Dr. Vincent Rajkumar: Thank you, Monty. Dr. Saad Usmani: Thank you so much. Dr. Monty Pal: And thank you so much to our listeners for your time today. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Monty Pal @montypal Dr. Vincent Rajkumar @VincentRK Dr. Saad Z. Usmani @szusmani Follow ASCO on social media: ASCO on X ASCO on Bluesky ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Monty Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Vincent Rajkumar: Honoraria: Research to Practice, Medscape Patents, Royalties, Other Intellectual Property: Authorship Royalties from Up To Date Dr. Saad Usmani: Consulting or Advisory Role: Janssen Oncology, GlaxoSmithKline, Abbvie, Bristol-Myers Squibb/Celgene, Regeneron, AstraZeneca, Sanofi Research Funding: Janssen Oncology, Bristol-Myers Squibb, K36 Therapeutics, Abbvie, Regeneron
© 2020-2026 Ivy Podcast Discovery LLC
